How is Prostate cancer diagnosed?

['ⵙⵎⴷ ⵜⴰⴱⵔⴰⵜ ⴰⴷ']

ⵎⴰⴽ ⴰ ⵙ ⵉⵜⵜⵡⴰⵙⵙⴰⵏ ⵓⴽⵏⵙⵉⵔ ⵏ ⴱⵔⵓⵙⵜⴰⵜ?

ⴷⴰ ⵉⵜⵜⵓⵙⵜⴰⵢ ⵓⴽⵏⵙⵉⵔ ⵏ ⵜⴰⴳⴳⴰⵢⵜ ⵏ ⵓⴱⵔⵓⵜⵉⵙⵜ ⵙ ⵓⵙⵎⵓⵏ ⵏ ⵉⵔⵉⵎⵏ ⴷ ⵜⵎⴳⴳⵉⵜⵉⵏ, ⵏⵏⴰ ⵉⵖⵉⵏ ⴰⴷ ⴳⵉⵏⵜ:

1. ⵉⵔⵉⵎ ⵏ ⵓⵅⵕⵓⵚ ⵙ ⵓⴹⵕⵉⵚ: ⴷⴰ ⵉⵙⵙⴽⵛⵎ ⵓⵊⵉⵊⵊⵉ ⵢⴰⵜ ⵜⴱⵔⵉⴷⵜ ⵉⵛⵕⵎⴹⵏ ⵙ ⵓⵅⵕⵓⵚ ⵉ ⵓⵅⵕⵓⵚ ⴰⴼⴰⴷ ⴰⴷ ⵉⵔⵎⵙ ⴰⴱⵔⵓⵜⴰⵙⵜⴰⵜ ⵎⴳ ⵉⵍⵍⴰ ⴽⵔⴰ ⵏ ⵓⵅⵕⵓⵚ.

2. ⴰⵙⴰⵔⵎ ⵏ ⴱⵔⵓⵙⵜⴰⵜ-ⵙⴱⵉⵙⵉⴼⵉⴽ ⴰⵏⵜⵉⴳⵉⵏ (ⴱⵙⵉⴰ): ⵉⴳⴰ ⴰⵙⴰⵔⵎ ⵏ ⵉⴷⴰⵎⵎⵏ ⵏⵏⴰ ⵉⵜⵜⵓⵙⵖⴰⵍⵏ ⴰⵙⵡⵉⵔ ⵏ ⴱⵙⵉⴰ, ⵢⴰⵏ ⵓⴱⵕⵓⵜⵉⵏ ⵉⵜⵜⵓⵙⴽⴰⵔⵏ ⵙⴳ ⵜⴱⵔⵓⵙⵜⴰⵜ.

ⵉⵖⵢ ⴰⴷ ⵉⴳ ⵓⵙⵡⵉⵔ ⵏ ⴱⵙⵉⴰ ⵢⴰⵜ ⵜⵎⴰⵜⴰⵔⵜ ⵏ ⵓⴱⴰⵢⵢⵓⵕ ⵏ ⵍⴱⵔⵓⵜⴰⵙⵉⵜ.

3. ⴰⵙⵎⵓⵜⵜⴳ ⵏ ⵓⴽⵙⴰⵢ ⵏ ⵓⵖⵢⴰⵢ ⵏ ⵓⵖⵢⴰⵢ ⵏ ⵓⵖⵢⴰⵢ (TRUS): ⴷⴰ ⵉⵜⵜⵓⵙⴽⵛⵎ ⵢⴰⵏ ⵓⵖⵢⴰⵢ ⴰⵎⵥⵥⵢⴰⵏ ⴳ ⵓⵖⵢⴰⵢ ⵏ ⵓⵖⵢⴰⵢ ⴰⴼⴰⴷ ⴰⴷ ⵉⵜⵜⵓⵙⴽⵔ ⵢⴰⵏ ⵓⵙⵡⵍⴼ ⵏ ⵓⵖⵢⴰⵢ ⵏ ⵓⵖⵢⴰⵢ ⵙ ⵓⵙⵎⵔⵙ ⵏ ⵉⵙⵎⵎⴰⵍⵏ ⵏ ⵓⵖⵢⴰⵢ.

ⴰⵢⴰ ⵉⵣⵎⵔ ⴰⴷ ⵢⴰⵡⵙ ⴳ ⵜⵓⵙⵙⵏⴰ ⵏ ⴽⵔⴰ ⵏ ⵜⵎⵓⴽⵔⵉⵙⵉⵏ ⴳ ⵜⴰⴱⵔⵓⵜⵉⵙⵜ.

4. ⴱⵉⵓⴱⵙⵉ: ⴷⴰ ⵉⵜⵜⵓⵙⴽⴰⵔ ⵢⴰⵏ ⵓⵙⵜⴰⵍ ⴰⵎⵥⵥⵢⴰⵏ ⵏ ⵜⴰⴳⴳⴰⵢⵜ ⵏ ⵓⴱⵔⵓⵜⴰⵙⵜ ⴷ ⵓⵣⵣⵔⴰⵢ ⵏⵏⵙ ⴷⴷⴰⵡ ⵏ ⵓⵎⵉⴽⵔⵓⵚⴽⵓⴱ ⵉ ⵜⵉⵍⵉⵜ ⵏ ⵜⵖⵔⴰⵙⵉⵏ ⵏ ⵍⴽⵓⵏⵚⵉⵕ.

ⴰⵢⴰ ⵉⴳⴰ ⵓⴱⵔⵉⴷ ⴰⵎⵢⵉⵡⵏ ⵏ ⵓⵙⵜⴰⵢ ⵏ ⵓⴱⴰⵢⵢⵓⵕ ⵏ ⵍⴱⵔⵓⵚⵟⴰⵜ.

5. ⵎⴰⴳⵏⵉⵜⵢ ⵔⵢⵣⵓⵏⴰⵏⵙ ⵉⴶⵉⵎⵉⵏⴶ (ⵎⵔⵉ): ⴰⴷⴷⵓⴱⴰⵜ ⴰⴷ ⵉⴾⴼⴰ ⵎⴰⴳⵏⵉⵜⵢ ⵔⵢⵣⵓⵏⴰⵏⵙ ⵉⴶⵉⵎⵉⵏⴶ ⵏ ⴱⵔⵓⵙⴰⵜⵢ ⴰⴷ ⵉⴾⴼⴰ ⴰⴾⴰⵉⴰⴷ ⵏ ⵉⴾⵉⴰⴷ ⵏ ⵉⴾⵉⴰⴷ ⵉⵉⵉⴰⴷ ⴷ ⴰⴷⴷⵓⴱⴰⵜ ⴰⴷ ⵉⴾⴼⴰ ⴰⴱⴰⵔⴰ ⵓⴰⵏ ⴱⵉⵓⴱⵙⵉ

6. ⵉⵔⵉⵎⵏ ⵏ ⵓⵊⵉⵏⵓⵎ: ⴽⵔⴰ ⵏ ⵉⵎⴰⵙⵙⴰⵏ ⵏ ⵜⵙⵏⵉⵊⵊⵉⵜ ⵖⵉⵏ ⴰⴷ ⵙⵎⵔⵙⵏ ⵉⵔⵉⵎⵏ ⵏ ⵓⵊⵉⵏⵓⵎ ⴰⴼⴰⴷ ⴰⴷ ⵙⵙⵏⵏ ⴰⵙⵎⴽⵍ ⵏ ⵓⴽⵏⵙⵉⵔ ⴷ ⴰⴷ ⵙⵙⵉⵔⵉⵡⵏ ⵜⵉⵖⵜⴰⵙⵉⵏ ⵏ ⵓⵙⵎⴽⵍ.

7. ⴰⵙⵉⴳⴳⵍ ⵏ ⵉⵖⵚⴰⵏ: ⵉⵖⵢ ⴰⴷ ⵉⵜⵜⵓⵙⴽⵔ ⴰⵙⵉⴳⴳⵍ ⵏ ⵉⵖⵚⴰⵏ ⴰⴼⴰⴷ ⴰⴷ ⵉⵜⵜⵓⵥⵕⴰ ⵉⵙ ⵜⴱⴰⵢⵢⵏ ⵜⵖⴰⵔⴰⵙⵜ ⵏ ⵓⴽⵏⵙⵉⵔ ⵖⵔ ⵉⵖⵚⴰⵏ.

8. ⴰⵙⵉⴳⴳⵍ ⵏ ⵓⴽⵓⵎⴱⵓⵜⵢⵓⵔ (ⵜⵛ.ⵜ): ⵉⵖⵢ ⴰⴷ ⵉⵜⵜⵓⵙⵎⵔⵙ ⵓⵙⵉⴳⴳⵍ ⵏ ⵜⵛ.ⵜ. ⴰⴼⴰⴷ ⴰⴷ ⵉⵜⵜⵓⵥⵕⴰ ⵉⵙ ⵜⴱⵉⴷⴷ ⵍⴽⵓⵏⵚⵉⵕ ⵖⵔ ⵉⴳⵎⴰⵎⵏ ⵢⴰⴹⵏ ⵏⵖⴷ ⵉⴳⵎⴰⵎⵏ ⵏ ⵡⴰⵏ.

ⵉⵇⵇⴰⵏⴷ ⴰⴷ ⵏⵙⵙⴽⵜⵉ ⵎⴰⵙ ⵓⵔ ⴷⴰ ⵜⵜⵡⴰⵜⵜⵓⵏ ⴽⵓⵍⵍⵓ ⵉⵔⴳⴰⵣⵏ ⵉⵍⴰⵏ ⵉⵙⵡⵉⵔⵏ ⵏ ⴱⵙⵉⴰ ⵉⵖⵍⴰⵍⵏ ⵏⵖⴷ ⵜⵉⵢⴰⴼⵓⵜⵉⵏ ⵏ ⴹⵕⵉ ⵉⵅⵛⴰⵏ, ⴽⵓⵔⵙⵜⴰⵏ ⵏ ⵜⴱⵕⵓⵚⵟⴰⵜ, ⴷ ⵓⵔ ⴷⴰ ⵜⵜⵡⴰⵜⵜⵓⵏ ⴽⵓⵍⵍⵓ ⴽⵓⵔⵙⵜⴰⵏ ⵏ ⵜⴱⵕⵓⵚⵟⴰⵜ ⵉⵙⵡⵉⵔⵏ ⵏ ⴱⵙⵉⴰ ⵉⵖⵍⴰⵍⵏ.

ⴼ ⵖⵉⴽⴰⵏ, ⵉⵇⵇⴰⵏ ⴰⴷ ⵉⵜⵜⵓⵙⴽⴰⵔ ⵓⵙⴼⵙⵉ ⵏ ⵓⵖⵢⴰⵢ ⴰⴼⴰⴷ ⴰⴷ ⵉⵜⵜⵓⵙⵙⵉⵙⵙⵏ ⵓⵙⵙⵉⵙⵙⵏ.

ⵙ ⵓⵙⵏⵓⵃⵢⵓ, ⴷⴰ ⵉⵜⵜⵓⵙⴽⴰⵔ ⵓⵖⵜⴰⵙ ⵏ ⵓⵙⵙⴽⵛⵎ ⵏ ⵜⴱⵢⵓⴱⵙⵉ ⴷⴼⴼⵉⵔ ⵏ ⵓⵙⵎⴽⵍ ⵏ ⵜⵢⴰⴼⵓⵜⵉⵏ ⵏ ⵉⵔⵉⵎⵏ ⴰⴷ ⴷ ⵉⵎⵙⴽⴰⵔⵏ ⵏ ⵓⵡⵓⵔⵔⵉ ⴷ ⵜⵣⵎⵎⴰⵔ ⵏ ⵓⴼⴳⴰⵏ.

['ⵉⵙⵓⵎⴰⵔ']

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Saldova R, Fan Y, Fitzpatrick JM, Watson RW, Rudd PM: Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. Glycobiology. 2011, 21 (2): 195-205.

Marenco J, Kasivisvanathan V, Emberton M: New standards in prostate biopsy. Arch Esp Urol. 2019, 72 (2): 142-149.

Moradi M, Mousavi P, Abolmaesumi P: Computer-aided diagnosis of prostate cancer with emphasis on ultrasound-based approaches: a review. Ultrasound Med Biol. 2007, 33 (7): 1010-28.

Cuperlovic-Culf M, Belacel N, Davey M, Ouellette RJ: Multi-gene biomarker panel for reference free prostate cancer diagnosis: determination and independent validation. Biomarkers. 2010, 15 (8): 693-706.

McGrath SE, Michael A, Morgan R, Pandha H: EN2: a novel prostate cancer biomarker. Biomark Med. 2013, 7 (6): 893-901.

An Y, Chang W, Wang W, Wu H, Pu K, Wu A, Qin Z, Tao Y, Yue Z, Wang P, Wang Z: A novel tetrapeptide fluorescence sensor for early diagnosis of prostate cancer based on imaging Zn2+ in healthy versus cancerous cells. J Adv Res. 2020, 24 (): 363-370.

[Consensus of Chinese experts on the application of molecular imaging targeting prostate specific membrane antigen in prostate cancer patients]. Zhonghua Wai Ke Za Zhi. 2018, 56 (2): 91-94.

Zhong WD, He HC, Bi XC, Ou RB, Jiang SA, Liu LS: cDNA macroarray for analysis of gene expression profiles in prostate cancer. Chin Med J (Engl). 2006, 119 (7): 570-3.

['ⴰⵙⴱⴷⵉⴷ: ⴰⵎⵙⵏⵉⵊⵊⵉ']

['ⴰⵙⵉⵜ ⴰⴷ ⵉⵜⵜⵓⴼⴽⴰ ⵖⴰⵙ ⵉ ⵓⵡⵜⵜⴰⵙ ⵏ ⵓⵙⵙⵍⵎⴷ ⴷ ⵓⵙⵏⵖⵎⵙ, ⵓⵔ ⵉⴳⵉ ⴰⵙⴼⴽ ⵏ ⵓⵎⵛⴰⵡⴰⵕ ⵏ ⵓⴷⵓⵙⵜⵓⵔ ⵏⵖⴷ ⵜⵡⵓⵔⵉⵡⵉⵏ ⵜⵉⵣⵣⵓⵍⴰⵏⵉⵏ.']

['ⵓⵔ ⵉⵇⵇⵉⵏ ⴰⴷ ⵉⵜⵜⵓⵙⵎⵔⵙ ⵓⵎⵍⴰⵏ ⵉⵜⵜⵓⴼⴽⴰⵏ ⴳ ⵓⵙⵎⵔⵙ ⵏ ⵓⵙⵎⵉⴳⵍ ⵏⵖⴷ ⵓⵙⵓⵊⵊⵉ ⵏ ⵜⵎⵓⴽⵔⵉⵙⵜ ⵏ ⵜⴷⵓⵙⵉ ⵏⵖⴷ ⵜⵎⴰⴹⵓⵏⵜ, ⴷ ⵡⵉⵏⵏⴰ ⵉⵔⴰⵏ ⴰⵙⵇⵇⵙⵉ ⴰⵎⵙⵏⵉⵊⵊⵉ ⴰⵡⵏ ⵉⵜⵜⵓⴼⴽⴰⵏ ⵉⵇⵇⴰⵏ ⴰⴷ ⵙⴰⵡⵍⵏ ⴷ ⵓⵎⵙⵏⵉⵊⵊⵉ ⵉⵜⵜⵓⵥⵍⴰⵢⵏ.']

['ⵙ ⵡⴰⵍⵍⵍⵉ ⵉⵜⵜⵓⵢⴰⵏⵏⴰ, ⵜⴰⵔⴰⵜⵙⴰ ⵏ ⵓⵏⵢⵓⵔⴰⵍ ⵏⵏⴰ ⵉⵜⵜⴰⴽⴽⴰⵏ ⵜⵉⵎⵔⴰⵔⵓⵜⵉⵏ ⵉ ⵉⵙⵇⵙⵉⵜⵏ, ⵓⵔ ⴷⴰ ⵜⵜⵉⵍⵉ ⴰⴽⴽⵡ ⵜⵓⵙⴷⵉⴷⵜ ⴳ ⵎⴰⴷ ⵉⵥⵍⵉⵏ ⵙ ⵓⵡⵏⵖ ⵏ ⵓⵟⵟⵓⵏ. ⵙ ⵓⵎⴷⵢⴰ, ⵓⵟⵟⵓⵏ ⵏ ⵎⴷⴷⵏ ⵉⵜⵜⵓⵙⵏⴼⴰⵍⵏ ⵖⴼ ⵜⵎⴰⴹⵓⵏⵜ ⵉⵥⵍⵉⵏ.']

['ⵚⵓⴰⵍ ⵙⵓⵍ ⴰⵙⵏⴰⵍ ⵏ ⵓⵊⵉⵊⵊⵉ ⵏⵏⴽ ⵏⵖⴷ ⴽⵔⴰ ⵏ ⵓⵎⵙⵙⵉⵡⵍ ⵏ ⵜⴷⵓⵙⵉ ⵢⴰⴹⵏ ⵉⵇⴱⵍⵏ ⴳ ⵎⴰⴷ ⵉⵥⵍⵉⵏ ⵙ ⵡⴰⴷⴷⴰⴷ ⵏ ⵜⴷⵓⵙⵉ. ⵓⵔ ⴰⴽⴽⵡ ⴰⴷ ⵜⵙⵙⴼⵍⴷ ⴰⵙⵏⴰⵍ ⵏ ⵓⵊⵉⵊⵊⵉ ⴰⵣⵣⵓⵍⴰⵏ ⵏⵖⴷ ⴰⴷ ⵜⵣⴰⵢⴷ ⴳ ⵓⵙⵓⵜⴳ ⵏⵏⵙ ⴰⵛⴽⵓ ⵏⵜⵜⴰⵜ ⴰⵢⴷ ⵜⵙⵙⵖⵔⴷ ⴳ ⵓⵙⵉⵜ ⴰⴷ. ⵎⴽ ⵜⵓⵔⴷⴰ ⴰⴷ ⵖⵓⵔⴽ ⵉⵍⵍⴰ ⵡⴰⴷⴷⴰⴷ ⵏ ⵜⴷⵓⵙⵉ ⵉⵣⵣⴳⵔⵏ, ⵙⵎⴷ 911 ⵏⵖⴷ ⴰⴷ ⴷⵉⴷⵜ ⵜⴰⵍⵙ ⴷⴰⵔ ⵜⴰⴷⴰⵍⴰ ⵏ ⵓⵣⵣⵔⴰⵢ ⵏ ⵣⵉⴽⴽ. ⵓⵔ ⵜⵍⵍⴰ ⵜⵓⵇⵇⵏⴰ ⵏ ⵓⵊⵉⵊⵊⵉ ⴷ ⵓⵎⵏⵉⴳ ⵙ ⵓⵙⵉⵜ ⴰⴷ ⵏⵖⴷ ⵓⵙⵎⵔⵙ ⵏⵏⵙ. ⵓⵔ ⴷⴰ ⵜⵙⴽⴰⵔ ⴱⵢⵓⵎⵉⴷⵍⵉⴱ ⵏⵖⴷ ⵉⵎⵙⵡⵓⵔⵉⵏ ⵏⵏⵙ ⵏⵖⴷ ⴽⵔⴰ ⵏ ⵓⵎⴷⵔⴰⵡ ⴳ ⵓⵙⵉⵜ ⴰⴷ ⴽⵔⴰ ⵏ ⵓⵙⵎⴷⵢⴰ, ⵙ ⵡⴰⵡⴰⵍ ⵏⵖⴷ ⵙ ⵓⵙⵏⵓⵎⵍ, ⴳ ⵎⴰⴷ ⵉⵥⵍⵉⵏ ⵙ ⵉⵏⵖⵎⵉⵙⵏ ⵉⵍⵍⴰⵏ ⴳ ⵓⴷⵖⴰⵔ ⴰⴷ ⵏⵖⴷ ⵓⵙⵎⵔⵙ ⵏⵏⵙ.']

['ⴰⵙⴱⴰⴷⵓ: ⵉⵣⵔⴼⴰⵏ ⵏ ⵓⴼⵓⵙ']

['ⴰⵛⵔⵓⵜ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ']

['ⵎⴽ ⵜⵛⵛⵉⵖⴰⵍⴷ ⵙ ⵜⵛⵛⵉⵢⵜ ⵎⴰⵙⴷ ⴽⵔⴰ ⵏ ⵜⵓⵎⴰⵢⵜ ⵏⵖⴷ ⵉⵙⵏⴼⴰⵔⵏ ⵏⵏⴰ ⵉⵜⵜⵓⴼⴽⴰⵏ ⴳ ⵡⴰⵙⵉⵜ ⵏⵏⵓⵏ ⵏⵖⴷ ⵜⵉⵙⵏⵙⵉ ⵏⵏⵓⵏ ⴷⴰ ⵉⴽⵛⵎⵏ ⴳ ⵉⵣⵔⴼⴰⵏ ⵏ ⵓⵣⵔⴼ ⵏⵏⵓⵏ, ⵜⵣⵎⵔⴷ ⴰⴷ ⵜⴰⵍⵙⴷ (ⵏⵖ ⴰⵎⴷⵢⴰⵣ ⵏⵏⴽ) ⴰⴷ ⵜⵙⵏⵎⵍⴷ ⵉ ⵡⴰⵙⵉⵜ ⵏⵏⵓⵏ ⵙ ⵓⵙⵓⵜⵔ ⵏ ⵓⵙⵙⵉⴷⴼ ⵏ ⵜⵓⵎⴰⵢⵜ ⵏⵖⴷ ⵉⵙⵏⴼⴰⵔⵏ, ⵏⵖⴷ ⴰⴷ ⵜⴱⴷⴷⴷ ⵜⵉⵍⵉⵜ ⵏⵏⵙⵏ.']

['ⵉⵏⴰⵓⴰⵏ ⴰⵂⴰⵏ ⴰⴾⵜⴰⴱ ⵙ ⴰⵍⴾⵉⵜⵜⴰⴱ ⵙ ⵎⵢⵍ (ⵉⴾⵉⴰⴷ ⵙ ⴰⴾⵜⴰⴱ "ⵎⵢⵍ" ⵉ ⵎⵢⵍ)']

['DMCA ⵜⵙⵙⵓⵜⵔ ⴰⵙⵎⵉⵙⵉ ⵏⵏⴽ ⵏ ⵓⵎⴳⴰⵍ ⵏ ⵉⵣⵔⴼⴰⵏ ⵏ ⵓⵎⴳⴰⵢ ⵉⴽⵛⵎ ⴳ ⵓⵙⵎⵎⴰⵍ ⴰⴷ: (1) ⴰⵙⵏⵓⵎⵍ ⵏ ⵜⵡⵓⵔⵉ ⵉⵃⴱⴰⵏ ⵉⵣⵔⴼⴰⵏ ⵏ ⵓⵎⴳⴰⵢ ⵏⵏⴰ ⵉⴳⴰⵏ ⴰⵙⵏⵜⵍ ⵏ ⵓⵎⴳⴰⵍ; (2) ⴰⵙⵏⵓⵎⵍ ⵏ ⵜⵓⵎⴰⵢⵜ ⵉⵃⴱⴰⵏ ⵉⵣⵔⴼⴰⵏ ⴷ ⵉⵏⵖⵎⵉⵙⵏ ⵉⵅⵚⵚⴰⵏ ⴰⴼⴰⴷ ⴰⴷ ⵏⴰⴼ ⵜⵓⵎⴰⵢⵜ; (3) ⵉⵏⵖⵎⵉⵙⵏ ⵏ ⵓⵎⵢⴰⵡⴰⴹ ⴰⴽⴷⴽ, ⴳ ⵉⵍⵍⴰ ⵡⴰⵏⵙⴰ ⵏⵏⴽ, ⵓⵟⵟⵓⵏ ⵏ ⵜⵉⵍⵉⴼⵓⵏ ⴷ ⵡⴰⵏⵙⴰ ⵏ ⵓⵍⵉⴽⵜⵕⵓⵏ; (4) ⴰⵙⵉⵡⴹ ⵏⵏⴽ ⵎⴰⵙ ⴷⴰⵔⴽ ⵜⴰⵍⵍⵉⵍⵜ ⵉⵖⵓⴷⴰⵏ ⵏ ⵓⵙⵏⴽⴷ ⵎⴰⵙ ⵜⵓⵎⴰⵢⵜ ⵙ ⵜⵖⴰⵔⴰⵙⵜ ⵏⵏⴰ ⵜⵙⵙⵔⴳⴰⵍ ⵓⵔ ⵜⴽⴽⵉ ⵜⵓⵔⴰⴳⵜ ⵙⴳ ⵖⵓⵔ ⵡⴰⵏⵏⴰ ⵉⵟⵟⴰⴼⵏ ⵉⵣⵔⴼⴰⵏ ⵏ ⵓⵎⴳⴰⵢ, ⵏⵖⴷ ⴰⵎⴷⵢⴰⵣ ⵏⵏⵙ, ⵏⵖⴷ ⵙ ⵓⵙⵡⵓⵔⵉ ⵏ ⴽⵔⴰ ⵏ ⵓⵙⵍⴳⵏ; ']

['(5) ⴰⵙⵉⵙⵙⵉⴾⵉ ⵏⵢⵜ, ⵉⴾⴼⴰⵏ ⵙ ⴰⵍⵆⴰⴾⵓⵎ ⵏ ⴰⵍⵆⴰⴾⵓⵎ ⵏ ⵜⵉⴷⵉⵜ, ⴰⵙ ⵉⵙⴰⵍⴰⵏ ⵓⵉⵏ ⵢⵎⵢⵍ ⵏⴰⵙⴰⵏ ⵓⵉⵏ ⵢⵎⵢⵍ ⵓⵉⵏ ⴰⴾⴰⵉⴰⴷ ⴷ ⴰⵙ ⵉⵍⴰ ⴰⴾⴰⵉⴰⴷ ⵉ ⴰⵙⵓⵋ ⵏ ⴰⵍⵆⴰⴾⵓⵎ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵜⵉⵏ ⴰⴾⴰⵉⴰⴷ ⵓⵉⵏ ⴰⴾⴰⵉⴰⴷ ⵓⵉ ⴰⵋⵋⴰⵏⵢⵏ']

['ⴷ (6) ⴰⴾⴰⵔⵓⵙ ⵏ ⵉⴾⵉⵜⴱⴰⵏ ⵏ ⵎⵓⵙⵏⴰⵜ ⵏ ⵉⴾⵉⵜⴱⴰⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜ ⵎⵢⵗ ⵓⴰ ⵉⵋⵋⴰⵏ ⵙ ⵢⵎⵢⵍ ⵏ ⵎⵓⵙⵏⴰⵜ ⵏ ⵉⴾⵉⵜⴱⴰⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜ']

['ⴰⴾⴰⵉⴰⴷ ⵏ ⴰⵙⴰⴾⵏⵢ ⵏ ⵉⵙⴰⵍⴰⵏ ⵓⵉⵏ ⴰⵋⵋⵓⵜⵏⵢⵏ ⴰⴷⴷⵓⴱⴰⵜ ⴰⴷ ⵢⵈⵈⵉⵍ ⴰⵙⵉⵓⴰⴷ ⵏ ⴰⴾⴰⵉⴰⴷ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜ ⵏⵢⵜ']

['ⴰⵎⵢⴰⵡⴰⴹ']

['ⵙⵓⴾⵢⵍ ⵉⵢⵎⴰⵍ ⵉⵢⵎⴰ ⵙ ⴽⴰⴾⴰⵎⴰⵍ ⴰⵙⵉⵙⵜⴰⵏ/ⴰⵙⵓⵋ']

How is prostate cancer diagnosed?

Prostate cancer is diagnosed through a combination of tests and procedures, which may include:

1. Digital Rectal Exam (DRE): A doctor inserts a gloved, lubricated finger into the rectum to feel the prostate for any abnormalities.

2. Prostate-Specific Antigen (PSA) Test: This is a blood test that measures the level of PSA, a protein produced by the prostate gland.

Elevated PSA levels may indicate the presence of prostate cancer.

3. Transrectal Ultrasound (TRUS): A small probe is inserted into the rectum to create an image of the prostate using sound waves.

This can help identify any abnormalities in the prostate gland.

4. Biopsy: A small sample of prostate tissue is removed and examined under a microscope for the presence of cancer cells.

This is the only definitive way to diagnose prostate cancer.

5. Magnetic Resonance Imaging (MRI): An MRI scan of the prostate can help identify any abnormalities and guide the biopsy procedure.

6. Genomic Testing: Some doctors may use genomic tests to help determine the aggressiveness of the cancer and guide treatment decisions.

7. Bone Scan: A bone scan may be performed to check if the cancer has spread to the bones.

8. Computed Tomography (CT) Scan: A CT scan may be used to check if the cancer has spread to other organs or tissues.

It is important to note that not all men with elevated PSA levels or abnormal DRE results will have prostate cancer, and not all prostate cancers will cause elevated PSA levels.

Therefore, a biopsy is necessary to confirm the diagnosis.

Additionally, the decision to undergo a biopsy is made after considering the results of these tests and the individual's risk factors and preferences.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.

['ⴰⵜⵜⴰⵢⵏ']

['ⴷⴰ ⵉⵙⵙⵎⵔⴰⵙ ⴱⵢⵓ ⵎⵉⴷⵍⵍⵉⴱ ⵉⵎⴰⵙⵙⵏ ⵏ ⵓⵙⵉⴳⴳⵍ ⵉⵎⵉⴽⵙⵉⵍⵏ (ⴰⵍⴳⵓⵔⵉⵜⵎ ⵏ ⵓⵍⵎⵎⵓⴷ ⵏ ⵉⵎⵉⵙ) ⵉ ⵓⵙⵓⴼⵖ ⵏ ⵉⵎⵣⵉⵏⵏ ⵏ ⵉⵙⵇⵙⵉⵜⵏ ⴷ ⵜⵎⵔⴰⵔⵓⵜⵉⵏ.']

['ⴷⴰ ⵏⵙⵙⵏⵜⵉ ⵙ 35 ⵎⵍⵢⵓⵏ ⵏ ⵜⵥⵕⵉⴳⵉⵏ ⵏ ⵜⵙⵏⵉⵊⵊⵉⵜ ⵜⴰⴱⵢⵓⵎⵉⴷⵉⴽⵜ ⵏ ⴱⴰⴱⵎⵉⴷ/ⵎⵉⴷⵍⵉⵏ. ⵓⵍⴰ ⴰⵡⴷ ⵜⵉⴼⵔⴽⵉⵏ ⵏ ⵡⵉⴱ ⵏ ⵔⴰⴼⵉⵏⴷⵡⵉⴱ.']

['ⴰⵜ-ⵓ-ⴰⵗ "ⴰⵍⵓⴰⵈⴰⵏ" ⴰⴷ "ⴰⴾⴼⴰⵣ"']